Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group |
|
Antiresorptives: Safety Concerns-Clinical Perspective. |
|
Assessment of the educational impact of an information leaflet on the knowledge of complications in systemic sclerosis. |
|
Charcot-Leyden crystals in synovial fluid |
|
A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: the IVORY trial Methodological considerations |
|
Comparative study of serum osteocalcin and of the histomorphometric evaluation of iliac biopsy in postmenopausal osteoporosis |
|
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. |
|
A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee |
|
Environmental factors associated with familial or non-familial forms of Paget's disease of bone |
|
Epidemiogenetic study of French families with Paget's disease of bone |
|
Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta. |
|
A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group |
|
Recognizing osteoporosis and its consequences in Quebec (ROCQ): background, rationale, and methods of an anti-fracture patient health-management programme. |
|
Romosozumab in postmenopausal women with low bone mineral density. |
|